ProCyte other research news

PRCY said it discovered a new class of non-peptide copper-based compounds that deliver copper (I). The first use of the compounds will be against HIV.

According to the company, copper alters the structure of HIV protease. Copper is known to have protein carriers in the blood, the most important of which is ceruloplasmin. Delivery of copper from ceruloplasmin involves the conversion of copper (II) to copper (I). Little has been known about how to deliver a stable form of copper (I), but PRCY's new technology uses copper (I) directly. The company's first-generation of copper-peptide compounds utilize copper (II). ...